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Abstract
Background: Many cancers are increased in immunosuppressed patients and evi-
dence is accumulating that immune dysfunction may be a contributing risk factor for 
second primary cancers (SPCs). The aim of this study was to explore the potential 
influence of immune mechanisms in SPC.
Methods: We used the Swedish Cancer Registry (1990-2015) to select 13 male and 
14 female first primary cancers (FPCs) that are known to be related to immune sup-
pression. We assessed relative risks (RRs) for any of these as concordant (same first 
and second cancer) and discordant FPC-SPC pairs. Hierarchical clustering of signifi-
cant RRs was performed for cancers as FPC and SPC.
Results: Concordant risks for SPCs were excessive in men and women for nasal 
(RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip 
(32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, 
tongue/mouth cancers, and non-Hodgkin lymphoma had multiple bidirectional as-
sociations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had 
associations mainly as FPC while liver and kidney cancers showed most associations 
as SPC.
Conclusions: Immune dysfunction may be a plausible contributing factor for most of 
the associations, which calls for experimental verification.
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1 |  INTRODUCTION
A report of multiple primary cancers in cancer patients dating 
back to 1921 stated that 4.7% of cancers appeared to be “of mul-
tiple growth”.1 Since then improvements in cancer survival have 
increased the probability of second primary cancers (SPCs) and 
higher order primaries. However, for most first primary cancers 
(FPCs) higher order primaries are rare, and thus, the focus has 
been on SPCs.2,3 The interest has been mainly twofold: one is a 
clinical interest because potentially carcinogenic therapies need 
to be balanced in favor of survival benefit, particularly in can-
cers of high cure rates, including Hodgkin lymphoma and tes-
ticular cancer.4,5 The second interest is in understanding human 
carcinogenesis because, in addition to atomic bomb survivors, 
smokers, and some occupational settings, radio- and chemother-
apy offer quantitative data on cancer risks in humans, including 
effects of dose, duration of exposure, and time from exposure to 
diagnosis.6-8 Outside a therapeutic setting, it is assumed that the 
causes of SPCs are the same as those of FPCs, including smok-
ing, infections, and family history.8 Thus, understanding causes 
of SPC may advance understanding of causes of cancer in gen-
eral. Recent molecular and clinical data provide evidence of the 
cross talk between the immune system and cancer cells, which 
involves, for example, local antitumor immune cell recruitment, 
tumor immunosuppression, immunoevasion, and the effects of 
chronic inflammation in carcinogenesis.9,10 It is well-known 
that iatrogenic immune suppression promotes appearance of 
many cancers, including squamous cell carcinoma (SCC) of 
the skin, nasal, and kidney cancers, non-Hodgkin lymphoma 
(NHL), and cancers in the oral cavity.11-15 It is conceivable that 
FPC may negatively influence immune function by suppressing 
antitumor defense mechanisms in ways that may mimic iatro-
genic immune suppression.16-19 Such a mechanism would thus 
promote SPCs that are known to be in excess in immunosup-
pressed organ transplantation patients.20-22
The main hypothesis of the study is that immune mech-
anisms contribute to the appearance of SPCs. In order to 
provide the evidence on the potential influence of immune 
mechanisms in SPC, we systematically compared relative 
risks (RRs) for immune responsive cancers bidirectionally, 
that is, when they are FPCs and SPCs.21,22 Cancers were 
identified from the Swedish Cancer Registry, and for immune 
responsive cancers, we selected those that were increased in a 
Swedish-Danish study on organ transplant recipients 14; RRs 
for all cancers were increased 3.5 times in Sweden and 2.9 
times in Denmark. As additional analyses, we assessed risks 
for “a single SPC after any FPC” and for “any SPC after a 
single FPC.” The former is a measure of collective carcino-
genic factors (eg, immune dysfunction) FPCs exert on a sin-
gle SPCs; the latter shows the influence of single factors (eg, 
carcinogenic therapy) on multiple SPCs.
2 |  PATIENTS AND METHODS
The Swedish Family-Cancer Database, which was updated in 
2015, includes data on more than 2.0 million cancer patients. 
Cancer diagnosis was recorded based on the 7th International 
Classification of Disease (ICD-7) and its later versions. The 
data originate from the Swedish Cancer Register which was 
founded in 1958.23 It is compulsory for every health-care pro-
vider to report newly detected cancer cases to a regional regis-
try which are located at the oncological centers in each of six 
medical regions. The regional registries follow the same rules 
of registration, and carry out coding, checking, and correction 
of the records. All new incident tumors are registered as sepa-
rate entities regardless of the morphology. Whether a tumor is a 
novel neoplasia, and thus, reportable, or a recurrence of an ear-
lier diagnosed cancer is subject to the clinician's evaluation.23 
This practice implies that concordant cancers in the same organ 
system are registers, deviating from the rules of the International 
Agency for Research on Cancer (IARC).23 However, these de-
viating rules only apply to the analyses shown in Table 1 while 
all other data are consistent with the IARC rules.
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The definition of “immune responsive cancer” was ad-
opted from the Swedish-Danish study on 20 804 solid organ 
transplant recipients.14 Immune responsive cancers were 
those with RRs over the mean RR of 3.2 for the two coun-
tries combined. In addition, chronic lymphocytic leukemia 
(CLL) was included because it was not included in the above 
study, but CLL is known to be immune responsive.24 Thus, 
cancers were included as immunosuppressive cancers: lip, 
tongue + mouth, salivary glands, anus, nose, liver, other fe-
male genitals (including vagina and vulva), kidney, skin (only 
squamous cell carcinoma, SCC), thyroid gland, connective 
tissue, and hematological tissues (NHL and CLL). Breast 
and prostate were included as reference sites as these are not 
considered immune responsive; in the above Swedish-Danish 
study the RRs for breast cancer were 1.1 (0.9-1.4) in Sweden 
and 1.3 (1.1-1.7) in Denmark, for prostate cancer they were 
0.9 (0.8-1.1) and 1.0 (0.7-1.4), respectively. Follow-up was 
from 1990 through 2015, and was ended at diagnosis of SPC, 
immigration or death, whichever came earliest.
RRs for SPC were estimated through the incidence of 
second immune responsive cancer divided by the incidence 
of same cancer diagnosed as FPC in the general population. 
When risks for concordant cancers were considered, the di-
agnoses in the first year were deleted while for discordant 
sites all diagnoses were considered. The estimation was done 
separately for men and women and adjusted for age, calen-
dar year, place of residence (four groups: big cities, South 
Sweden, North Sweden, or unspecified), and socioeconomic 
factors (six groups: blue-collar worker, white-collar worker, 
farmer, private, professional, or other/unspecified). Poisson 
regression model was employed for the risk estimation. For 
a collective assessment of the entire set of cancers, we calcu-
lated risks for a “single SPC after any FPC” (RR calculated for 
the single SPC) and, conversely, for “any SPC after a single 
FPC” (RR calculated all SPC, excluding concordant, breast, 
and prostate cancers) separately for men and women. In these 
analyses, concordant cancers as well as breast and prostate 
cancers were not included as these would have skewed the 
results: concordant cancers with high risks and breast and 
prostate cancers with low risk and vast case numbers.
Hierarchical clustering of significant RRs was performed 
for cancers as FPC and SPC. The cluster was based on 
“Euclidean” by using R package “pheatmap.” The statisti-
cal tests were two-tailed and P value < .05 was regarded as 
significant. All the analyses were performed in SAS 9.4 and 
figures were generated in R 3.5.
The study was approved by the local ethical committee 
without requirement for informed consent.
3 |  RESULTS
The data on concordant cancers are shown in Table 1, giving 
the numbers of FPCs and of SPCs, RRs and 95% confidence 
intervals (95%CIs). For 13 male cancers, case numbers ranged 
from 803 (anus) to 28 324 (skin SCC); 185 081 prostate can-
cers constituted the reference site. For 14 female cancers, nasal 
cancer was identified in 573 patients and that of skin cancer in 
T A B L E  1  Risk of second primary cancers on the concordant sites after the first year of first cancer diagnosis in men and women
Cancer site
Men Women
N1 N2 RR 95% CI N1 N2 RR 95% CI
Lip 2010 36 32.4 23.2 45.2 1045 14 61.2 36.1 104.0
Tongue and mouth 4386 100 51.7 42.4 63.1 3398 127 100.8 84.3 120.4
Salivary 1051 0 0 0 1006 0 0 0
Anus 803 3 37.5 12.0 116.5 1819 4 9.3 3.5 24.9
Nose 831 5 59.3 24.6 142.9 573 6 150.6 67.3 337.1
Liver 10 990 20 4.3 2.8 6.7 10 939 12 2.8 1.6 4.8
Breast — — — — 143 819 5759 1.8 1.8 1.9
Female genital — — — — 4450 47 17.4 13.1 23.3
Prostate 185 081 106 0.01 0.01 0.01 1045 — — — —
Kidney 13 922 68 2.9 2.3 3.7 9520 64 5.8 4.6 7.5
SCC of the skin 28 324 3626 13.2 12.7 13.6 23 032 2136 13.7 13.1 14.3
Thyroid 2213 4 8.4 3.2 22.5 5758 8 2.5 1.2 5.0
Connective tissue 3564 11 8.5 4.7 15.4 2903 14 19.7 11.6 33.3
NHL 18 414 78 2.00 1.6 2.5 15 152 55 2.0 1. 6 2.6
CLL 5828 3 0.5 0.2 1.5 3844 5 1.9 0. 8 4.5
Abbreviations: CLL, chronic lymphocytic leukemia; N1, number of first primary cancer; N2, number of second primary cancer; NHL, non-Hodgkin lymphoma; SCC, 
squamous cell carcinoma.
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23 032 patients; the reference site of breast cancer had 143 819 
patients. Among male cancers, RRs were increased for all but 
prostate cancer and CLL. Among female cancers, no increase 
was observed for CLL; salivary gland cancers had no SPCs. 
Very high risks of 10 or more were observed for lip (RR of 32.4 
for men and 61.2 for women), tongue/mouth (51.7, 100.8), anal 
(37.5 and 9.3), nasal (59.3 and 150.6), female genital (17.4), 
skin SCC (13.2, 13.7), and connective tissue (8.5, 19.7) cancers. 
The RRs were identical between sexes for skin SCC and also for 
NHL but they were significantly different (95%CIs did not over-
lap) for tongue/mouth and kidney cancers, female RRs being 
twofold higher than the male RRs. Large but nonsignificant sex 
differences were observed for anal and thyroid cancers (male 
excess), and for lip, nasal, and connective tissue cancers (female 
excess). These results were based on follow-up that commenced 
1 year after FPC; when follow-up was started immediately after 
the diagnosis of FPC, the RRs were much higher for salivary 
gland, kidney, and thyroid cancers while for other SPC the RRs 
were not different, considering sample sizes (data not shown).
Results for discordant male and female analyses are shown 
in Table S1. Results are shown when any sex-specific RR was 
significant.
Based on the significant male RRs, a heatmap based on 
hierarchical clustering is presented as Figure  1 (note that 
concordant associations were left blank). The figure clearly 
shows that FPCs (read in vertical direction) of the tongue/
mouth, skin, thyroid, and anus had many strong associations 
and NHL had also many but weaker associations. Skin, and 
tongue/mouth cancers were associated with most other sites 
as SPCs (horizontal direction); kidney cancer was also a com-
mon SPC but the associations were relatively weak. Based on 
FPCs, clustering was observed on the top of the heatmap, in-
cluding cancers of the tongue/mouth, skin, thyroid, and anus. 
Similarly, cancers of the nose, lip, and salivary glands clus-
tered together, as well as CLL, NHL, and connective tissue 
cancer. Considering clustering by SPC (left side of the heat-
map), lip and nasal cancer, NHL and CLL, and tongue/mouth 
cancer and skin clustered together. The reference site, prostate, 
showed weak associations with kidney as FPC as well as SPC.
In Figure 2, discordant female cancers are shown, and in 
agreement with male cancers, skin, tongue/mouth cancers, 
and NHL as FPCs show multiple associations. Female geni-
tal and salivary gland cancers show a few but strong associa-
tions. Lip, connective tissue, skin, tongue/mouth, and kidney 
cancer were common SPCs. Hierarchical clustering shows 
some similarities with male clustering. FPCs of the tongue/
mouth and skin cancers clustered together (top of the heat-
map), and were joined by female genital, lip, and salivary 
gland cancers. Liver and connective tissue cancers clustered, 
as did NHL and CLL. SPC clusters (left side of the heat-
map) include cancer of the salivary glands and nose as one, 
and lip, anal, connective tissue, and skin cancers as another 
F I G U R E  1  Heatmap of RRs for male first primary cancers (FPC, 
vertical, cancer listed in the bottom) and second primary cancers (SPC, 
horizontal, cancer listed on the right). The RR scale is shown in the top 
right corner. Only significant associations (95%CIs not overlapping 
with 1.00) were included; RRs of the insignificant or concordant 




F I G U R E  2  Heatmap of RRs for female first primary cancers 
(FPC, vertical, cancer listed in the bottom) and second primary 
cancers (SPC, horizontal, cancer listed on the right). The RR scale is 
shown in the top right corner. Only significant associations (95%CIs 
not overlapping with 1.00) were included; RRs of the insignificant 
or concordant associations were assigned as 1. NHL, non-Hodgkin 
lymphoma, CLL, Chronic lymphocytic leukemia
FPC
SPC
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cluster. The reference site breast showed weak associations 
as FPC as well as SPC.
We assessed risks for “a single SPC after any FPC” and, 
conversely, for “any SPC after a single FPC” for men and 
women (Figure 3). The detailed data are presented as Tables 
S2 and S3, respectively. Among “single SPC after any FPC,” 
the highest risks were noted for lip (7.24 female, 4.72 male), 
salivary gland, and skin cancers, the latter with a large male 
excess (3.86 vs 2.66). Anal cancer was only increased among 
women while liver cancer was increased only among men.
For “risk for any cancer after single cancer” (Figure 3), 
liver cancer (1.79 male, 1.87 female) ranked first, followed 
by nasal (only male RR of 1.61 was significant) and tongue/
mouth cancers (1.64 and 1.32). For salivary gland and anal 
cancer only female RRs were significant.
4 |  DISCUSSION
The long-suspected role of immune surveillance in human 
cancer has gained strong experimental support in the past 
decade and, even more gratifying, that these scientific 
breakthroughs have also benefited clinical oncology in the 
context of diagnostics, prognostication, drug development, 
and therapy.10,25-27 The recent scientific discoveries on the 
role of immunological factors in cancer were accomplished 
a few decades later than it had become known that iatrogenic 
immune suppression poses a large risk of cancer.11,28,29 Why 
some cancers are particularly responsive to immune sup-
pression or immunotherapy is not well understood but one 
general correlation with immune responsive tumors is their 
F I G U R E  3  RRs for a single second 
primary cancer after any first primary 
cancer (top), and RRs for any second 
primary cancer after a single first primary 
cancer (bottom). Male data are blue and 
female data in yellow symbols. The vertical 
bars show 95%CIs. NHL, non-Hodgkin 
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mutational load, although there are also others, for exam-
ple, PDL1 expression and CD8+ cell infiltration.30 Further 
insight is being gained by detailed cell type classifications 
considering immune cell repertoire in tumor infiltration and 
stroma.29-32 Immunoscores have been devised for clinical 
prognostication; for example, a successful immunoscore for 
colon cancer included counts of CD3+ and CD8+ T-cells in 
the tumor and in in the invasive margin.33
The generally higher risk for SPC than for FPC, and the se-
lective influence on particular cancers has been suggested to 
have immunological mechanisms.8,21,22 In the present study, we 
focused on cancers that showed a higher than average risk in 
immunosuppressed patients and provide strong epidemiologi-
cal evidence on the role of immune factors in SPC causation. 
Many of the analyzed immune responsive cancers were rare and 
hardly any literature exists on these cancers in the context of 
SPCs, which is particularly true of the included solid cancers.
First, we demonstrated that concordant risks for SPCs 
were excessive both in men and women for nasal (RRs 59.3 
for men and 150.6 for women), tongue/mouth (51.7 and 
100.8), and lip (32.4 and 61.2) cancers and a few others. 
The access to concordant second cancers is rather unique 
to the Swedish Cancer Registry as SPCs are recorded even 
in the same organ system, opposite to the rule of IARC, as 
discussed under Methods. The caveat in concordant cancers 
is that one cannot exclude the possibility that SPC may be 
metastasis from FPC. However starting the follow-up 1 year 
after diagnosis did not change the risk estimates for most of 
the cancers analyzed in this study; the exceptions were sali-
vary gland, kidney, and thyroid cancers for which the imme-
diate follow-up showed higher risks than the subsequent one. 
It is known that for kidney cancer the bilateral tumor is often 
diagnosed synchronously with the first tumor.34 The causes 
for these cancers with a very high risk are not known and 
are probably interactions of immune dysfunction and exter-
nal causes. Human papilloma viruses (HPVs) contribute to a 
minor portion of cancers in the oral cavity and large portions 
of female genital and anal cancers.35,36 Epstein-Barr virus is 
associated with nasopharyngeal cancer and may also con-
tribute to cancer of the nasal cavity.35,36 The very high risks 
should alert clinicians to a long-term follow-up of patients 
with these cancers; whether the diagnosed SPCs are actually 
metastases may not influence treatment.
The heatmaps showed that some cancers had multiple 
associations bidirectionally as FPC and SPC in men and 
women; these typically included skin SCC, tongue/mouth 
cancer, and NHL. Some cancers had associations mainly 
as FPC, including nasal cancer and CLL, and in male anal 
and thyroid cancers. A few cancers showed associations 
mainly as SPC, including liver and kidney cancers, and we 
can speculate that their immune functions are particularly 
influences by FPCs. Clustering analyses showed similari-
ties between cancers either as FPC or SPC. FPC clusters 
included tongue/mouth and skin cancers, lip and salivary 
gland cancers, liver and connective tissue cancers, as well 
as NHL and CLL. SPC clusters include salivary glands and 
nose as one, and lip, anal, connective tissue, and skin can-
cers as another cluster.
The novel type of analysis “risk for a single SPC after any 
FPC” and “risk for any SPC after a single FPC” was revealing in 
many ways, although detection bias should not be excluded as a 
potential cause. First it showed that almost for any single cancer, 
the risks were significant indicating existence of common, col-
lective carcinogenic factors. Notably, the highest increases were 
recorded for cancers of the lip, salivary gland, nose, and skin, 
known to respond after immune suppressive therapy. Among 
the reference cancers, prostate cancer was not increased after 
any cancer and the RR for breast cancer was only 1.13. Risk 
of “any SPC after single cancer” is likely to reflect treatment 
related effects and, accordingly, cancers of the skin, kidney, and 
oral cavity, for which primary treatment is surgery, were only 
modestly increased, at level no higher than breast and prostate 
cancers (1.22 and 1.23). Male and female risks did not differ for 
“any cancer after single cancer” but for “single cancer after any 
cancer” only female risk was significant for anal cancer and the 
male RR was higher than the female one for skin cancer.
The explanation for discordant associations is difficult 
to find among environmental risk factors for such a diverse 
set of cancers, including solid and hematological malig-
nancies. Even if some of these malignancies are treated 
with chemo- and/or radiotherapy, many are at least ini-
tially treated with surgery (skin SCC, lip, tongue/mouth, 
salivary glands) and therapy-related SPCs would not be 
very probable. Surveillance bias may generally influence 
SPCs, particularly in anatomic proximal to FPCs, but in-
creased risks of diverse SPC such as depicted in Figure 3 
suggest mainly other causes. Immune dysfunction may be 
a plausible contributing factor as the selection criteria for 
cancer types specified that had to be increased in immu-
nosuppressed patients more than average cancers.
The present study was nation-wide but many of the in-
cluded cancer sites were rare with the consequence of limited 
statistical power. Another limitation was the number of com-
parisons whereby chance findings were unavoidable. As lim-
ited literature has been published SPC in a similar context, it 
was not possible to conform the finding through the existing 
literature. However, the applied bidirectional analysis helped 
to some extent to alert about chance findings. Finally, the 
definition of “immune responsive cancer” was operational 
and based on the findings from excess cancers in immuno-
suppressed organ transplant patients.
In conclusion, the results show novel associations of many 
rare cancers in the setting of SPCs that are potentially related 
to immunological response. Cancers of the lip, tongue/mouth, 
salivary glands, nose, connective tissue, and CLL were found 
to be associated with many SPCs with high risk and many of 
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them presented also high risks as SPCs. The results call for 
experimental studies to search for the putative immunological 
mechanisms and mechanisms of carcinogenesis influencing 
SPC risks. The high risks recorded should justify vigilance 
SPC surveillance, and help target follow-up to high-risk SPCs.
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